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Supplementary	Information		
Supplementary	Figure	1.	Clonal	and	subclonal	neoantigen	burden.		
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Supplementary	Figure	2.	Plots	of	somatic	mutation	counts	split	by	the	96	mutation	types.	
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A.	Normalised	mutation	spectrums	 for	Tumours	1-4.	Plots	are	based	on	 the	 following	SNV	
burdens:	 Tumour	 1:	 1653,	 Tumour	 2:	 1766,	 Tumour	 3:	 4662	 amd	 Tumour	 4:	 1738.	 	 B.	
Normalised	 mutation	 profiles	 split	 by	 private,	 shared	 and	 truncal	 mutations	 for	 each	
tumour.	Plots	are	based	on	the	following	SNV	burdens:	Tumour	1:	835	private,	490	shared,	
328	truncal,	Tumour	2:	480	private,	495	shared,	791	truncal,	Tumour	3:	2002	private,	1698	
shared,	962	truncal,	Tumour	4:	580	private,	660	shared,	498	truncal.	
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Supplementary	Figure	3.	Allele	specific	copy	number	profiles	of	individual	tumour	regions.		
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Supplementary	Figure	4.	An	Illustration	of	Phylogenetic	conflict	in	Tumour	1.	
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Supplementary	Figure	5.	Mapping	of	phylogenetic	trees	onto	tumour	maps.		
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Supplementary	Figure	6.	MLH1	promoter	methylation.	
	
qPCR	of	bisulfite	converted	DNA	confirms	MLH1	promoter	methylation	in	Tumour	2-4	but	
not	Tumour	1.	NonMeth=Human	Non-Methylated	DNA	Standard;	Meth=Human	Methylated	
DNA	Standard;	NTC=Non-template	control.		 	
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Supplementary	Figure	7.	Possible	neoantigen	loss	due	to	HLA	mutations.	
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Supplementary	Figure	8.	Paired-end	reads	demonstrate	biallelic	inactivation	of	B2M.		
	
	
Screenshots	from	the	Interactive	Genome	Viewer	of	Tumour	2	AE	displaying	the	B2M	splice-
site	 and	 frameshift	mutations.	 Paired	 reads	 that	 cover	 both	mutation	 loci	 are	 highlighted	
with	red	boxes.	A.	A	total	of	4	read	pairs	showed	the	B2M	splice-site	mutation	and	covered	
the	location	of	the	B2M	frameshift	mutation	but	none	showed	the	frameshift	mutation.	B.	A	
total	of	ten	read	pairs	showed	the	B2M	frameshift	mutation	and	covered	the	location	of	the	
B2M	splice	site	mutations	but	none	showed	the	B2M	splice-site	mutation.	
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Supplementary	Figure	9.	Trunk	overestimation	by	single	region	analysis.	
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Supplementary	Figure	10.	Mutation	copy	number	of	chromosome	8	in	the	STAD	TCGA	
series.	
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Supplementary	Table	1.	Cell	purity	and	ploidy	
Sample	 Purity	 Ploidy	
Tumor	1	F	 0.72	 1.82	
Tumor	1	U	 0.6	 1.8	
Tumor	1	Z	 0.61	 1.9	
Tumor	1	AD	 0.23	 3.19	
Tumor	1	AQ	 0.26	 3.15	
Tumor	1	AW	 0.37	 2.97	
Tumor	1	BH	 0.33	 2.79	
Tumor	2	Y	 0.34	 2.07	
Tumor	2	AL	 0.37	 2.1	
Tumor	2	S	 0.32	 2.1	
Tumor	2	T	 0.28	 2.12	
Tumor	2	AE	 0.41	 2.07	
Tumor	2	AK	 0.15	 2.15	
Tumor	2	E	 0.32	 2.14	
Tumor	2	N	 0.28	 2.07	
Tumor	2	P	 0.26	 2.1	
Tumor	3	Y	 0.5	 2.22	
Tumor	3	AE	 0.82	 2.04	
Tumor	3	H	 0.51	 2.12	
Tumor	3	N	 0.54	 2.03	
Tumor	3	P	 0.64	 2.15	
Tumor	3	T	 0.62	 2.12	
Tumor	3	B	 0.49	 2.02	
Tumor	3	G	 0.5	 2.05	
Tumor	3	AD	 0.43	 2.02	
Tumor	4	M	 0.38	 3.81	
Tumor	4	Q	 0.34	 3.63	
Tumor	4	X	 0.37	 3.69	
Tumor	4	Z	 0.25	 3.43	
Tumor	4	AB	 0.37	 3.76	
Tumor	4	AC	 0.32	 3.27	
Tumor	4	AF	 0.33	 3.45	
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Supplementary	Table	2.	COSMIC	signatures	
    
COSMIC	Signature	
	  
 
3	 4	 6	 7	 14	 15	 17	
Lymph	Node	
Metastases	
(subclonal	
only)	
0.075143	 0.0609702	 0.4732131	 0.0693594	 0.0595752	 0.1420577	 0.0575242	
	
Supplementary	Table	3.	dN/dS	
		 dN/dS	 CI95%	
Tumour1.Truncal	 1.06	 0.83-1.35	
Tumour1.Shared	 1.07	 0.87-1.31	
Tumour1.Private	 1.16	 0.99-1.37	
Tumour2.Truncal	 1.04	 0.89-1.21	
Tumour2.Shared	 1.05	 0.86-1.28	
Tumour2.Private	 1.31	 1.05-1.63	
Tumour3.Truncal	 1.01	 0.87-1.17	
Tumour3.Shared	 1.01	 0.9-1.12	
Tumour3.Private	 1.01	 0.91-1.12	
Tumour4.Truncal	 0.95	 0.77-1.16	
Tumour4.Shared	 0.83	 0.7-0.98	
Tumour4.Private	 0.90	 0.75-1.09	
	
	
	
	
	
	
